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ORIGINAL ARTICLE
Subcortical brain alterations in major depressive disorder:
findings from the ENIGMA Major Depressive Disorder
working group
L Schmaal1, DJ Veltman1, TGM van Erp2, PG Sämann3, T Frodl4,5, N Jahanshad6, E Loehrer7, H Tiemeier7,8, A Hofman7, WJ Niessen9,10,
MW Vernooij7,9, MA Ikram7,9,11, K Wittfeld12, HJ Grabe12,13,14, A Block13, K Hegenscheid15, H Völzke16, D Hoehn3, M Czisch3,
J Lagopoulos17, SN Hatton17, IB Hickie17, R Goya-Maldonado18, B Krämer18, O Gruber18, B Couvy-Duchesne19,20,21, ME Rentería22,
LT Strike19,20,21, NT Mills22,23, GI de Zubicaray20, KL McMahon21, SE Medland24, NG Martin22, NA Gillespie25, MJ Wright19, GB Hall26,
GM MacQueen27, EM Frey4, A Carballedo28, LS van Velzen1, MJ van Tol29, NJ van der Wee30,31, IM Veer32, H Walter32, K Schnell33,
E Schramm34, C Normann34, D Schoepf35, C Konrad36, B Zurowski37, T Nickson38, AM McIntosh38,39, M Papmeyer38, HC Whalley38,
JE Sussmann38, BR Godlewska40, PJ Cowen40, FH Fischer41,42, M Rose41,43, BWJH Penninx1, PM Thompson6 and DP Hibar6 for the
ENIGMA-Major Depressive Disorder Working Group44
The pattern of structural brain alterations associated with major depressive disorder (MDD) remains unresolved. This is in part due to
small sample sizes of neuroimaging studies resulting in limited statistical power, disease heterogeneity and the complex interactions
between clinical characteristics and brain morphology. To address this, we meta-analyzed three-dimensional brain magnetic
resonance imaging data from 1728 MDD patients and 7199 controls from 15 research samples worldwide, to identify subcortical brain
volumes that robustly discriminate MDD patients from healthy controls. Relative to controls, patients had significantly lower
hippocampal volumes (Cohen’s d=− 0.14, % difference=− 1.24). This effect was driven by patients with recurrent MDD (Cohen’s
d=− 0.17, % difference=− 1.44), and we detected no differences between first episode patients and controls. Age of onset ⩽ 21 was
associated with a smaller hippocampus (Cohen’s d=− 0.20, % difference=− 1.85) and a trend toward smaller amygdala (Cohen’s
d=− 0.11, % difference=− 1.23) and larger lateral ventricles (Cohen’s d=0.12, % difference= 5.11). Symptom severity at study
inclusion was not associated with any regional brain volumes. Sample characteristics such as mean age, proportion of antidepressant
users and proportion of remitted patients, and methodological characteristics did not significantly moderate alterations in brain
volumes in MDD. Samples with a higher proportion of antipsychotic medication users showed larger caudate volumes in MDD
patients compared with controls. This currently largest worldwide effort to identify subcortical brain alterations showed robust smaller
hippocampal volumes in MDD patients, moderated by age of onset and first episode versus recurrent episode status.
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INTRODUCTION
With a lifetime prevalence of 416%,1 major depressive disorder
(MDD) is a very common psychiatric disease and is among the
leading causes of disability worldwide.2 Despite intensive research
aimed at identifying neurobiological substrates of depression in
the last decades, our understanding of the pathophysiological
mechanisms underlying depression is still rudimentary. Widely
available structural magnetic resonance imaging has led to
hypotheses of (para-)limbic circuits being involved in MDD, but
still the exact pattern of structural brain alterations associated with
MDD remains unresolved, perhaps due to small sample sizes,
disease heterogeneity and the complex interactions between
clinical characteristics and brain morphology. Therefore, in the
current study we meta-analyzed structural magnetic resonance
imaging data of a very large sample (n= 8927) to identify
subcortical brain volumes that robustly discriminate MDD patients
from healthy controls.
Many studies have found structural alterations in various
subcortical brain regions in MDD. To date, volumetric differences
have not always been consistent and are poorly replicated for
some regions; moreover, sample sizes are often small, limiting the
power to detect subtle brain differences. Meta–analyses represent
useful tools to identify the most robust findings across studies,
and indicate that morphological changes in MDD are regional
rather than global.3–5 Hippocampal volume reduction (one of the
most extensively studied regions) in MDD has been one of the
most widely replicated findings.3 However, the association
between MDD and hippocampal volume reduction is likely
complex, and hippocampal volumes may be smaller, on average,
in patients with recurrent MDD compared to patients early in the
course of adult-onset MDD.6 Other factors may modulate the
effect size of morphological changes in the hippocampus in MDD,
including disease severity, childhood maltreatment, age of onset,
antidepressant medication and illness duration.6,7
Amygdala volume abnormalities in MDD are inconsistently
reported and may depend on the illness phase, medication use
and family history of MDD. A current first episode and
antidepressant use has been associated with enlarged amygdala
volume (for example, van Eijndhoven et al.,8 Frodl et al.9 and
Hamilton et al.10), but a greater number of episodes and a family
history of MDD have been associated with smaller amygdala
volume (for example, Hronenberg et al.11 and Saleh et al.12). Other
brain regions have been less extensively investigated, including
prefrontal areas, thalamus and striatum.
Sources of inconsistency in prior findings are multifactorial.
Demographic characteristics of the samples such as age and sex
may partly explain differences in effect sizes across studies. Clinical
characteristics of MDD samples are another major source of
heterogeneity. Moreover, differences in data acquisition protocols
and processing, differences in statistical analyses performed and
potential publication bias further complicate the interpretation of
findings from retrospective meta-analyses. For instance, different
automated or manual segmentation algorithms may show subtle
differences in their estimates of subcortical volumes.13
To address the limited statistical power of prior studies and
overcome some of the issues of retrospective meta-analyses
based on aggregated results from single studies, we initiated the
Major Depressive Disorder Working Group within the Enhancing
Neuro Imaging Genetics through Meta-Analysis (ENIGMA) con-
sortium. This is an international collaboration currently evaluating
15 research samples from six different countries worldwide,
including neuroimaging data from 1728 MDD patients and 7199
healthy individuals. The primary aim of our ENIGMA-MDD Working
Group is to identify imaging markers that robustly discriminate
MDD patients from healthy controls using an individual partici-
pant data (IPD)-based meta-analysis. This IPD-based meta-analytic
approach applied to data from our consortium provided us with
the opportunity to plan a priori, standardize and harmonize data
processing and statistical models across all samples, and to assess
the influence of participant-level covariates, not all of which are
reported in the literature, thereby addressing some of the
limitations related to retrospective meta-analyses. Imaging mar-
kers identified through our consortium could help to prioritize
brain measures for future genetic analyses, and may enhance our
understanding of the etiology of MDD.
Here, we investigated subcortical gray matter, lateral ventricle
and total intracranial volume (ICV) alterations in MDD patients
compared to healthy individuals by performing the largest meta-
analysis to date. As additional exploratory analyses, we examined
potential modulating effects of demographic, clinical and
methodological characteristics on morphological differences in
MDD patients.
SUBJECTS AND METHODS
Samples
The ENIGMA-MDD Working Group includes 15 international samples with
neuroimaging and clinical data from MDD patients and healthy controls
(participating sites are shown in Supplementary Figure S1). None of the
research groups that we approached refused to participate in the ENIGMA-
MDD consortium. Moreover, we are continuously encouraging new
research groups to join in on our ongoing consortium work to increase
our sample size and thereby increase statistical power and generalizability
of our results. Detailed demographics for each sample are found in
Supplementary Table S1 and clinical characteristics in Supplementary
Table S2. Exclusion criteria for study enrollment in each sample are given in
Supplementary Table S3. In total, we analyzed data from 8927 people
including 1728 MDD patients and 7199 healthy controls. All participating
sites obtained approval from local institutional review boards and ethics
committees. All study participants provided written informed consent at
their local institution.
Image processing and analysis
Structural T1-weighted magnetic resonance imaging brain scans were
acquired at each site and analyzed locally using the fully automated and
validated segmentation software FreeSurfer.14 Image acquisition para-
meters and software descriptions for each sample are given in
Supplementary Table S4. The segmentations of seven subcortical gray
matter regions (nucleus accumbens, amygdala, caudate, hippocampus,
pallidum, putamen and thalamus), lateral ventricles and total ICV were
visually inspected for accuracy following standardized protocols designed
to facilitate harmonized image analysis across multiple sites (http://
enigma.ini.usc.edu/protocols/imaging-protocols/). Further details on image
exclusion criteria and quality control can be found in Supplementary
Information SI1.
Statistical framework of meta-analysis
We examined patient versus control group differences within each sample
using multiple linear regression models, where the mean ((left+right)/ 2)
region of interest volume was the outcome measure and a binary indicator
of diagnosis (0 = controls, 1 = patients) was the predictor of interest. All
models were controlled for age, sex and ICV. Additional covariates were
included whenever necessary to control for scanner differences. Effect size
estimates were calculated using Cohen’s d-metric computed from the t-
statistic of the diagnosis indicator variable from the regression models.
Throughout the manuscript we report uncorrected P-values with a
significance threshold determined by Bonferroni correction for testing
nine regions of interest (P= 0.05/9 = 5.6 × 10− 3).
To explore the influence of sex on subcortical brain volume differences
between patients and controls, we performed diagnosis-by-sex interaction
effects within each sample. To further investigate the sources of regional
brain changes in MDD, we performed separate stratified meta-analyses
comparing age of onset (early onset ⩽ 21 years, late onset 421 years15)
and stage of illness (first and recurrent episode patients). Further, we
investigated whether symptom severity at the time of scanning was
associated with brain changes using the 17-item Hamilton Depression
Rating Scale (HDRS-1716) and the Beck Depression Inventory (BDI-II17).
Subcortical volume alterations in depression
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All regression models and effect size estimates were fit at each site
separately and a final Cohen’s d-effect size estimate was obtained using an
inverse variance-weighted random-effect meta-analysis model in R (metafor
package, version 1.9-118). The meta-analysis of symptom severity scores was
an exception: severity scores were treated as continuous variables, so effect
sizes were in terms of Pearson's r, a partial-correlation after removing
nuisance variables (age, sex, ICV and scan center). The final meta-analyzed
Pearson's r was estimated following the same inverse variance-weighted
random-effect meta-analysis model used for all other meta-analyses. See
Supplementary Information SI1 for full meta-analysis details.
Moderator analyses with meta-regression
We tested whether mean age of each sample (Supplementary Table S1),
magnetic resonance field strength, FreeSurfer version used for image
processing (Supplementary Table S4), percentage of patients acutely
depressed, percentage of patients with a co-occurring anxiety disorder,
percentage of patients taking antidepressants and the percentage of
patients taking antipsychotics (Supplementary Table S2) explained a
significant proportion of the variance in effect sizes across sites in the
meta-analysis. Each moderator variable was separately included as a fixed
effect predictor in a meta-regression model.
RESULTS
Effect sizes for group differences in subcortical volumes
Comparison of brain volumes in MDD patients and healthy
controls. In our primary analysis, we assessed case-control
differences between all MDD patients (n= 1728) compared with
all healthy controls (n= 7199) across nine brain structures
(Figure 1). Only mean hippocampal volume was significantly
lower in MDD patients compared to healthy controls (Cohen’s d
(95% confidence interval): d=− 0.14 (−0.22, − 0.06); P-value =
4.60 × 10− 4, % difference =− 1.25). Case-control differences for all
structures are listed in Table 1. No significant diagnosis-by-sex
interaction effects on any of the region of interest volumes were
observed (Supplementary Table S16).
Influence of recurrence status on brain volume. We examined how
the current stage of a depressed patient may relate to brain
volumes by splitting the sample into first episode (n= 583) and
recurrent episode patients (n= 1119) and compared to healthy
controls (Figure 2a). We did not detect any significant differences
between first episode patients and healthy controls (all P-values
40.3). Recurrent episode patients showed lower mean hippo-
campal volume than controls (d=− 0.17 (−0.25, − 0.10);
P-value = 1.12 × 10− 5, % difference =− 1.44). Full meta-analyzed
recurrence status differences are listed in Supplementary Table S5
and Supplementary Table S6. Relative to the full MDD sample,
recurrent patients showed larger effect sizes compared to
controls. However, no significant differences were detected
between recurrent and first episode patients (Supplementary
Table S7).
Influence of age of onset of depression on brain volume. We
examined how the age of onset modulates volumetric brain
changes (Figure 2b). Patients with an early age of onset (⩽21 years;
n= 541) showed significantly lower mean hippocampal volumes
than controls (d=− 0.20 (−0.31, − 0.10); P-value = 2.31 × 10− 4,
% difference =− 1.85). In addition, we found lower amygdala
volume (d=− 0.12 (−0.23, − 0.01); P-value = 0.033, % difference =
− 1.23) and higher mean lateral ventricle volume (d= 0.14
(0.04, 0.25); P-value = 0.009, % difference = 5.11) in early onset
patients compared to controls, but neither survived correction
for multiple comparisons. Although sample sizes were too small to
split first and recurrent episode patients into early and late onset
groups, only about half (57%) of the early onset MDD patients had
a recurrent episode, and the percentage of recurrent episode
patients did not moderate the result of smaller hippocampal
volumes in early onset MDD patients (P= 0.54), suggesting that
this effect is at least partly independent of recurrence status.
Patients with a late age of onset (421 years; n= 997) showed no
detectable brain volumetric differences compared to controls.
Full age of onset effect sizes are listed in Supplementary Table S8
and Supplementary Table S9. The effect sizes in early episode
patients are larger than those obtained when considering the full
Figure 1. Cohen's d-effect sizes 95% CI and for differences in
subcortical brain volumes between major depressive disorder
(MDD) patients and healthy control subjects. Effect sizes were
corrected for age, sex and intracranial volume (ICV). The effect size
for ICV was corrected for age and sex. *Po0.05 corrected. CI,
confidence interval.
Table 1. Full meta-analytic results for each mean structure for the MDD patients versus controls comparison controlling for age, sex, scan center
and ICV
Cohen's da
(MDD—CTL)
Standard
error
95% CI % Difference P-value I2 Number of
controls
Number of
patients
Lateral ventricles 0.056 0.037 − 0.017–0.129 1.345 0.130 12.162 7058 1689
Thalamus − 0.044 0.038 − 0.119–0.031 − 0.398 0.250 15.067 7046 1682
Caudate − 0.023 0.050 − 0.121–0.074 − 0.232 0.641 45.729 7034 1681
Putamen 0.012 0.034 − 0.054–0.078 0.104 0.722 0.005 6957 1656
Pallidum − 0.001 0.034 − 0.067–0.065 − 0.049 0.972 0.000 7018 1657
Hippocampus − 0.144 0.041 − 0.225 to − 0.064 − 1.245 4.60 × 10− 4 24.813 7040 1700
Amygdala − 0.060 0.036 − 0.132–0.011 − 0.658 0.097 10.152 7060 1696
Accumbens − 0.019 0.034 − 0.085–0.047 − 0.203 0.569 0.000 6967 1652
ICV − 0.029 0.052 − 0.131–0.073 −0.212 0.575 51.476 7199 1728
Abbreviations: CI, confidence intervals; CTL, control; ICV, intracranial volume; MDD, major depressive disorder. aIncluded samples: all samples. Adjusted
Cohen's d is reported.
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sample. However, there were no detectable differences between
early and late onset patients (see Supplementary Table S10).
Association of MDD symptoms severity with subcortical volumes
We did not detect any significant associations between symptom
severity at study inclusion and brain volumes using the HDRS-17
(n= 667) and BDI-II (n= 667) questionnaires. Full effect sizes of
severity scores are available in Supplementary Table S11 and
Supplementary Table S12.
Moderator analyses
Using meta-regression, we tested whether hypothesized moder-
ating factors influenced the effect size estimates of all brain
volumes across samples included in the meta-analysis. Mean age
of each sample, magnetic resonance field strength, percent of
patients with a co-occurring anxiety disorder, and percent of
acutely depressed patients in each sample did not moderate
differences for subcortical volumes. We found an influence of the
FreeSurfer version used at each site on amygdala volume
(β=− 0.31; P-value = 0.049), but this was not significant after
correcting for multiple comparisons. We also found an influence of
percentage of patients taking antidepressants on hippocampal
effect size estimates (β=− 0.0023; P-value = 0.038), but again this
was not significant after correction for multiple comparisons.
Finally, we found a near-significant effect of antipsychotic drug
use on mean caudate volume (β= 0.016; P-value = 6.71 × 10− 3),
implying that caudate volume of depressed patients was greater
as the percentage of patients taking antipsychotic drugs was
higher (Supplementary Figure S7). Full results from each of the
moderator analyses are available in Supplementary Table S15.
Power analysis
With 1728 MDD patients and 7199 controls, we were able to
detect brain volume differences as small as Cohen’s d= 0.0751
at a nominal significance level P-value = 0.05 and 80% power
(and Cohen’s d= 0.0968 at our study significance threshold
P-value = 5.6 × 10− 3). On the basis of the final meta-analyzed
effect sizes found in this study, to detect mean differences in
hippocampal volumes between MDD patients and controls, a
study in the general MDD population at large would require 802
subjects per group to have 80% power to detect a difference at P-
value = 0.05. When focusing analyses on recurrent MDD patients
and controls, 545 subjects per group would be needed to provide
80% power to detect a difference in hippocampal volume at
P-value = 0.05. When focusing analyses on early age of onset MDD
patients (⩽21 years) and controls, 394 subjects per group would
be needed to have 80% power to detect a difference in
hippocampal volume at P-value = 0.05. See Supplementary
Information SI2 for full details of the power analysis.
DISCUSSION
This worldwide effort to identify subcortical gray matter, lateral
ventricle and total ICV alterations associated with MDD using an
IPD-based meta-analytic approach showed robust reductions in
hippocampal volume (1.24%) in MDD patients compared with
healthy controls. These hippocampal volume reductions were
mainly present in recurrent and/or early onset (⩽21 years) MDD,
whereas hippocampal volume reductions were absent in first
episode patients and less pronounced in patients with later age of
onset (421 years) MDD. Furthermore, smaller amygdala volume
and larger lateral ventricles volume were found in early onset
MDD, but neither survived correction for multiple comparisons.
Our finding of smaller hippocampal volume in MDD is in line
with previous retrospective meta-analyses of aggregated data.3–6
This robust finding of smaller hippocampal volume is often linked
to the ‘neurotrophic hypothesis of depression’. This proposes that
elevated glucocorticoid levels associated with chronic hyperacti-
vity of the hypothalamic–pituitary–adrenal axis in MDD may
induce brain atrophy via remodeling and downregulation of
growth factors including brain-derived neurotrophic factor.19 This
process may preferentially target the hippocampus, a major site in
the glucocorticoid negative feedback loop of the hypothalamic–
pituitary–adrenal axis with high expression of glucocorticoid
receptors.20 In animal models of depression, stress-induced
increases in glucocorticoid levels may result in regression of den-
dritic processes, inhibition of neurogenesis and loss of neurons.21
We only observed hippocampal volume deficits in recurrent
MDD and not in first episode patients. There is also direct
evidence from longitudinal studies that hippocampal volume
progressively decreases during the course of the disease, beyond
levels expected from normal aging.22 We also found that
Figure 2. (a) Cohen's d-effect sizes 95% CI for differences in subcortical brain volumes between recurrent major depressive disorder (MDD)
patients and healthy control subjects (striped pattern) and between first episode MDD patients and healthy controls (no pattern). (b) Cohen's
d-effect sizes 95% CI for differences in subcortical brain volumes between early onset (⩽21) MDD patients and healthy control subjects (no
pattern) and between later onset (>21) MDD patients and healthy controls (striped pattern). Effect sizes were corrected for age, sex and
intracranial volume (ICV). *Po0.05 corrected, **Po0.05. CI, confidence interval.
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hippocampal volume reductions were more pronounced in early
onset patients (⩽21 years), consistent with prior findings of smaller
hippocampal volume in early onset depression.23 Several factors,
including early life stress, temperamental low effortful control and
family history of depression have been linked to early onset
depression,24–26 as well as smaller hippocampal volume.27,28
Patterns of abnormal hippocampal development may predate
adolescent depression onset29 and smaller hippocampal volumes
have been found to predict a protracted response to antidepres-
sant treatment over weeks30,31and a more severe long-term illness
course,32 so morphological hippocampal alterations may repre-
sent risk markers for depression, recurrence and chronicity. As we
only observed hippocampal volume reduction in recurrent
patients and no subcortical volume alterations in first episode
patients, the current finding of smaller hippocampal volume in
early onset depression may reflect a longer illness duration and/or
greater number of episodes in patients with early onset MDD
instead of a premorbid vulnerability factor. Nonetheless, as only
about half (57%) of the early onset patients in our meta-analysis
had a recurrent episode and as the percentage of recurrent epi-
sode patients did not moderate the result of smaller hippocampal
volumes in early onset patients (post hoc test, P= 0.54), we
conclude that early disease onset is (in part) independently
associated with lower hippocampal volumes. Unfortunately, for
many of the samples complete information on the exact number
of episodes and duration of each episode was not available and
simply calculating disease burden as current age minus age of
onset is unsatisfactory, given the relapsing and remitting nature of
MDD. Clearly, there is a continued need for longitudinal studies
tracking hippocampal volume changes over the disease course, to
further elucidate whether hippocampal abnormalities result from
prolonged duration of chronic stress (that is, ‘scarring‘), represent
a vulnerability factor for MDD, or both.
Prior structural neuroimaging studies in depression have yiel-
ded conflicting results regarding alterations in amygdala volume
(for example, van Eijndhoven et al.,8 Frodl et al.,9 Kronenberg
et al.11 and Hickie et al.33). Our meta-analysis suggested smaller
amygdala volume in early onset MDD, but this effect was not
significant after correction for multiple comparisons. This is
consistent with a previous retrospective meta-analysis of aggre-
gated amygdala volume data by Hamilton et al.,10 which also
failed to detect a reliable difference in amygdala volume between
depressed patients and controls. However, prior meta-analyses
have shown larger amygdala volume in samples with a higher
proportion of patients taking antidepressants.3,10 We could not
replicate this result in the current meta-analysis.
Furthermore, our controlled meta-analysis could not replicate
findings of smaller caudate and putamen volumes observed in
prior smaller meta-analyses.3,5 Our current observations suggest
that subcortical alterations in MDD are either very small or limited
to the hippocampus (and to a lesser extent the amygdala) rather
than widespread. Reduced hippocampal volume is not specific to
MDD, as it has been observed in other psychiatric disorders, such
as schizophrenia, posttraumatic stress disorder, borderline person-
ality disorder and obsessive-compulsive disorder.34 Interestingly,
IPD-based meta-analytic studies of both schizophrenia35 and
bipolar disorder (Hibar et al., submitted), using highly similar
protocols, reported more widespread alterations in subcortical
volumes. Generally, detrimental effects of schizophrenia and
bipolar disorder on subcortical brain volumes appear greater than
those in MDD, although a study design directly comparing
patients with these disorders is clearly needed to resolve this.
The current study is the first to meta-analyze the relationship
between symptom severity at study inclusion and subcortical
volumes in MDD patients. Previous studies have yielded conflict-
ing results; most studies found no correlations between depres-
sive symptom severity and brain volume (for example, Kronenberg
et al.,11 Hickie et al.36 and Frodl et al.37), but some studies found
positive8,38 as well as inverse associations39 with, for example,
amygdala and hippocampal volumes. Our meta-analyses, based
on the HDRS-17 (n= 667) and BDI-II (n= 667) questionnaires,
found no evidence of association between symptom severity
and subcortical gray matter volumes. As severity of an entire
depressive episode is not fully characterized by depression
severity at study inclusion and given the predictive value of
hippocampal volume,30–32 this result awaits further investigation
in prospective longitudinal treatment designs.
With respect to the moderating effects of medication use, no
significant effect of the percentage of patients taking antidepres-
sants was observed, only a trend-wise lower hippocampal volume
in MDD patients in samples with a higher percentage of patients
taking antidepressants. Antidepressant treatment may block
hippocampal atrophy, to some extent, by enhancing synaptic
plasticity, neurotrophic processes and putatively neurogenesis,40
which appears to contradict our current observation. However,
confounding interactions between antidepressant use and
clinical characteristics cannot be ruled out, as samples with a
higher percentage of antidepressant users are likely to include
more severe MDD patients. Indeed, when performing a post hoc
analysis, the trend effect of lower hippocampal volume in
antidepressant medication users compared to controls disap-
peared when controlling for recurrence in the regression model.
However, intervention studies with pre- and post-antidepressant
treatment comparisons are needed to clarify the impact of
antidepressant use on hippocampal volume.
We found that an increase in the percentage of patients taking
antipsychotic drugs was associated with larger caudate volume in
depressed patients relative to controls. This is in line with prior
observations of caudate enlargement following antipsychotic
treatment in patients with schizophrenia and can occur as early
as 3 weeks post-exposure41,42 (but see Crespo-Facorro et al.43).
A key strength of our study is the IPD meta-analytic approach,
which increased the power to detect small effects by combining
data from 8927 individuals, while ensuring low methodological
heterogeneity by standardizing brain segmentation techniques
and statistical models across all participating samples. Moreover,
this IPD-based approach allowed us to systematically investigate
the effects of clinical characteristics such as recurrence status, age
of onset and severity of symptoms on brain alterations in MDD
patients.
Nonetheless, our study has some limitations. First, we could not
directly examine the influence of remission of MDD on brain
volume. In most studies, the majority of patients were acutely
depressed at the time of scanning, yielding groups of remitted
patients that were too small to properly investigate how remission
relates to brain volume. However, the proportion of MDD patients
in remission at each site had no moderating effect on differences
in brain volume when examined in a meta-regression analysis (see
Supplementary Table S15). Moreover, an additional meta-analysis
including only samples with a current diagnosis of MDD patients
at the time of scanning revealed very similar results (see Supple-
mentary Table S13), so remission status presumably did not have a
major impact on our current findings. A second limitation is the
variety of questionnaires used by the different sites to assess
severity of depressive symptoms; scores from different studies
were not directly comparable. Because pooling results from
different severity measures in a meta-analysis may lead to biased
results,44 we limited the meta-analysis with respect to severity of
symptoms to a selection of studies using the same instrument,
which considerably reduced the sample size. Finally, we restricted
our analyses to subcortical gray matter, lateral ventricle and total
ICVs and did not include cortical measures. As efforts such as the
current one require significant work in harmonization and quality
control by all sites, the current study is only a first step toward
identifying robust brain volume alterations in MDD patients.
Because prior studies have shown a potentially important role of
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especially the anterior cingulate cortex,45 the important next step
within our consortium will be examining cortical brain alterations
associated with MDD.
Despite these limitations, results of this first initiative of the
ENIGMA-MDD working group clearly indicate a key role of the
hippocampus in the pathophysiology of MDD, showing robust
hippocampal volume reductions particularly in recurrent and early
onset MDD. Brain changes in other subcortical regions in MDD
were less evident. Our findings together with the observations of
associations between smaller hippocampal volume and exe-
cutive impairments,37 learning and memory deficits36 and worse
treatment response46 in MDD, suggest that the hippocampus is a
prime target region for future research aimed at further unraveling
the pathophysiology of MDD and improving treatment.
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